港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

MIRXES-B

46.200

+0.0200.04%

成交量：9.73万

成交额：448.16万

市值：127.67亿

市盈率：-60.08

高：47.000

开：47.000

低：45.020

收：46.180

52周最高：48.700

52周最低：27.050

股本：2.76亿

香港流通股本：2.76亿

量比：0.48

换手率：0.04%

股息：- -

股息率：- -

每股收益(LYR):-0.769

净资产收益率：--

总资产收益率：-51.53%

市净率：-7.84

市盈率(LYR):-60.08

市销率: 80.60

数据加载中...

总览公司新闻公告

MIRXES-B(02629)公布中期业绩权益股东应占亏损约2835.23万美元同比收窄36.22%

MIRXES-B(02629.HK)获纳入恒生综合指数有望成为港股通标的

下周备忘

港股异动 | MIRXES-B(02629)涨超8%创新高以部署基于血液microRNA等检测设备方式进军印尼市场

MIRXES-B附属与印尼公司签署癌症早检合作谅解备忘录

MIRXES-B（02629）累涨93%创新高：技术与资本共振 “震荡-突破” 循环

MIRXES-B(02629)附属与一间印尼上市公司订立一份谅解备忘录

港股异动 | MIRXES-B(02629)涨近9%创新高公司在基于miRNA的癌症早期检测领域优势显著

MIRXES-B08月11日主力净流入4.7万元散户资金抛售

MIRXES-B08月06日主力净流入44.5万元散户资金抛售

MIRXES-B07月31日主力净流出61万元散户资金买入

觅瑞、NAGAWA联合发起万人癌筛，鸠山由纪夫应邀助力亚洲癌症预防

MIRXES-B07月24日主力净流出115.4万元散户资金买入

《大行》国证国际：22只非A+H股份可望成为港股通新贵当中15只在今年新上市

觅瑞MIRXES：“借道”“零人”第三方 “擦边”布局限制类业务

MIRXES-B07月14日遭主力抛售133.2万元

MIRXES-B07月10日遭主力抛售152.6万元

觅瑞MIRXES：自诩“唯一获批”现信披疑云核心产品特异性或低于国内两款产品

MIRXES-B(02629)股价下跌8.219%，现价港币$30.15

阿斯达克财经

医疗IPO沸腾了

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02629/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02629","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02629\",,,,,undefined,":{"symbol":"02629","market":"HK","secType":"STK","nameCN":"MIRXES-B","latestPrice":46.2,"timestamp":1756179195826,"preClose":46.18,"halted":0,"volume":97300,"delay":0,"floatShares":276342331,"shares":276342331,"eps":-0.76899,"marketStatus":"交易中","change":0.02,"latestTime":"08-26 11:36:23","open":47,"high":47,"low":45.02,"amount":4481578,"amplitude":0.042876,"askPrice":46.34,"askSize":1400,"bidPrice":46.2,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-0.76899,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1756180800000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":46.18,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.477515,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02629\",,,,,undefined,":{"symbol":"02629","floatShares":276342331,"roa":"-51.53%","roe":"--","lyrEps":-0.76899,"volumeRatio":0.477515,"shares":276342331,"dividePrice":0,"high":47,"amplitude":0.042876,"preClose":46.18,"low":45.02,"week52Low":27.05,"pbRate":"-7.84","psRate":"80.60","week52High":48.7,"institutionHeld":0,"latestPrice":46.2,"committee":-0.647059,"eps":-0.76899,"divideRate":0,"volume":97300,"delay":0,"ttmEps":-0.76899,"open":47,"prevYearClose":23.3,"prevWeekClose":45.82,"prevMonthClose":30.55,"prevQuarterClose":34.5,"fiveDayClose":48.36,"twentyDayClose":31,"sixtyDayClose":28.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02629\",params:#limit:5,,,undefined,":[{"date":"2025-08-25","symbol":"02629","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02629\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02629\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02629\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02629","date":"2025-08-25","current":-16.849413,"percent":0.015625,"low":-17.63001,"twenty":-12.493638,"median":-11.382498,"eighty":-10.789519,"high":-10.373055,"avg":-11.989697,"sd":1.72626,"marketCap":12152035222},"quantilePoints":[{"date":"2025-05-30","current":-10.615633,"twenty":-10.820807,"median":-10.729406,"eighty":-10.614136,"marketCap":7683833445},{"date":"2025-06-06","current":-10.752673,"twenty":-10.811558,"median":-10.713624,"eighty":-10.576495,"marketCap":7789091437},{"date":"2025-06-13","current":-10.566273,"twenty":-10.761884,"median":-10.608146,"eighty":-10.555773,"marketCap":7657518947},{"date":"2025-06-20","current":-12.580768,"twenty":-10.923966,"median":-10.686264,"eighty":-10.56693,"marketCap":9117973591},{"date":"2025-06-27","current":-12.5082,"twenty":-12.340962,"median":-10.752673,"eighty":-10.581112,"marketCap":9065344595},{"date":"2025-07-04","current":-11.927039,"twenty":-12.355485,"median":-10.862871,"eighty":-10.586526,"marketCap":8644312625},{"date":"2025-07-11","current":-11.200931,"twenty":-12.261215,"median":-11.092147,"eighty":-10.600008,"marketCap":8118022663},{"date":"2025-07-18","current":-11.402889,"twenty":-12.217621,"median":-11.255392,"eighty":-10.612638,"marketCap":8262752403},{"date":"2025-07-25","current":-11.182791,"twenty":-12.077376,"median":-11.219171,"eighty":-10.651065,"marketCap":8104865414},{"date":"2025-08-01","current":-11.128301,"twenty":-11.949795,"median":-11.200931,"eighty":-10.68858,"marketCap":8065393667},{"date":"2025-08-08","current":-11.930929,"twenty":-11.952128,"median":-11.246394,"eighty":-10.71678,"marketCap":8646944075},{"date":"2025-08-15","current":-16.088166,"twenty":-12.119645,"median":-11.255421,"eighty":-10.743366,"marketCap":11636271059},{"date":"2025-08-22","current":-16.714103,"twenty":-12.435432,"median":-11.355275,"eighty":-10.780307,"marketCap":12057303029},{"date":"2025-08-25","current":-16.849413,"twenty":-12.493638,"median":-11.382498,"eighty":-10.789519,"marketCap":12152035222}],"updateTime":1756179315544},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02629\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562228787","title":"MIRXES-B(02629)公布中期业绩 权益股东应占亏损约2835.23万美元 同比收窄36.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562228787","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562228787?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 22:50","pubTimestamp":1756133455,"startTime":"0","endTime":"0","summary":"智通财经APP讯，MIRXES-B(02629)公布2025年中期业绩，收益为1050万美元，同比增加9.4%。 公司权益股东应占亏损约2835.23万美元，同比收窄36.22%;每股亏损0.185美元。公告称，收益同比增加主要是由于早期检测及精准多组学分部的 GASTROClearTM及LUNGClearTM产生的收益增加，抵销了因终止FortitudeTM产品销售而导致的传染病分部收益减少260万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2561474741","title":"MIRXES-B(02629.HK)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474741","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474741?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 20:42","pubTimestamp":1755866540,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0028","HSTECH","LU1979443071.USD","LU2148510915.USD","513600","BK1564","HSI","HSCI","159271","HSImain","LU1064131003.USD","LU1328615791.USD","159982","07226","YANG","LU1580142542.USD","BK0012","BK4614","601688","BK1161","BK0183","HHImain","MHImain","LU1934453819.USD","02629","MCHmain","06886","HTSC.UK","HSCEI","BK1147","LU1064130708.USD","02833","BK0276","399300","BK0188","LU1781817850.SGD"],"gpt_icon":0},{"id":"2561147331","title":"下周备忘","url":"https://stock-news.laohu8.com/highlight/detail?id=2561147331","media":"AASTOCKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561147331?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 18:13","pubTimestamp":1755857580,"startTime":"0","endTime":"0","summary":"8月25日(周一)英国假期休市新西兰次季零售销售季率：预测转跌0.3%；前值升0.8%新加坡7月CPI年率：预测升0.8%；前值升0.8%新加坡7月CPI月率：预测跌0.3%；前值跌0.1%日本6月领先指标终值：初值106.1日本6月同步指标终值：初值116.8德国8月IFO商业景气指数：预测88.5；前值88.6德国...","market":"us","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180504113903359_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180504113903359_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.aastocks.com/sc/forex/news/comment.aspx?source=AAFN&id=NOW.1463592&catg=1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_forex","symbols":["06690","01658","06699","01610","01133","01618","06160","00358","00751","01628","01771","01896","02126","02196","02192","02186","02360","00753","02100","00604","02391","00347","01787","00670","02050","02367","02899","02400","00966","02388","01112","03990","02629","00586","02150","00636","02172","02555","01375","02601","03899","02162","02648","01585","00267","02390","00363","00631","01157"],"gpt_icon":1},{"id":"2560976825","title":"港股异动 | MIRXES-B(02629)涨超8%创新高 以部署基于血液microRNA等检测设备方式进军印尼市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2560976825","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560976825?lang=zh_cn&edition=fundamental","pubTime":"2025-08-18 10:43","pubTimestamp":1755485010,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，MIRXES-B涨超8%，盘中高见47.8港元创上市新高。公告称，透过与PT DIASTIKA BIOTEKINDO合作，该集团可：透过PT DIASTIKA BIOTEKINDO现有渠道即时透过部署基于血液的microRNA或多组学高发病率癌症检测设备方式进军印尼市场；利用印尼推行本地化政策及以东盟为中心的医疗器械框架实现监管灵活性；及利用印尼作为示范性开业地区将业务复制至东南亚、中东、北非及其他地区，从而实现全球规模扩展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2560992414","title":"MIRXES-B附属与印尼公司签署癌症早检合作谅解备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2560992414","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560992414?lang=zh_cn&edition=fundamental","pubTime":"2025-08-17 15:24","pubTimestamp":1755415453,"startTime":"0","endTime":"0","summary":"8月15日，MIRXES-B（02629）发布公告，公司的间接全资附属公司MiRXESPTE.LTD.与印尼上市公司PTDIASTIKABIOTEKINDO签订了一份为期12个月的谅解备忘录，双方将就高发病率及高死亡率癌症的早期检测及诊断进行合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508173486139020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2559928279","title":"MIRXES-B（02629）累涨93%创新高：技术与资本共振 “震荡-突破” 循环","url":"https://stock-news.laohu8.com/highlight/detail?id=2559928279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559928279?lang=zh_cn&edition=fundamental","pubTime":"2025-08-16 20:40","pubTimestamp":1755348001,"startTime":"0","endTime":"0","summary":"港股生物科技板块于8月15日再现强势标的——MIRXES-B，盘中一度冲高至44.98港元，刷新上市以来历史高点，较IPO发行价23.3港元累计涨幅已超93%，成为近期医药新股中的领涨品种。MIRXES-B作为“迎通概念”股，入通似乎已是板上钉钉。公开资料显示，MIRXES-B上市初期就凭借“惜货回拨”助推股价上涨。果不其然，MIRXES-B暗盘暴涨33.91%，首日涨幅28.76%。综上，MIRXES-B自上市以来呈现典型的“震荡洗盘—强势突破”周期循环，资金操盘手法高度结构化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2559914384","title":"MIRXES-B(02629)附属与一间印尼上市公司订立一份谅解备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2559914384","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559914384?lang=zh_cn&edition=fundamental","pubTime":"2025-08-15 20:50","pubTimestamp":1755262210,"startTime":"0","endTime":"0","summary":"智通财经APP讯，MIRXES-B 公布，公司的间接全资附属公司MiRXES PTE. LTD.近期已与PT DIASTIKA BIOTEKINDO订立一份谅解备忘录，据此，双方同意在印尼进行用于高发病率及高死亡率癌症早期检测及诊断的分子诊断检测及相关仪器的注册及商业化方面进行合作。谅解备忘录期限自签署日期起计为期12个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2559996010","title":"港股异动 | MIRXES-B(02629)涨近9%创新高 公司在基于miRNA的癌症早期检测领域优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2559996010","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559996010?lang=zh_cn&edition=fundamental","pubTime":"2025-08-15 11:03","pubTimestamp":1755227035,"startTime":"0","endTime":"0","summary":"公开资料显示，Mirxes觅瑞是一家以新加坡为总部的RNA生物科技公司，致力于开发及商业化针对癌症及其他疾病早期筛查的精准、无创、可负担的血液miRNA检测。公司旗舰产品GASTROClear/觅小卫是一款基于血液miRNA的胃癌筛查分子检测试剂盒，已在包括新加坡及欧盟的多国获批，并取得美国FDA突破性医疗器械认证。国元国际认为，公司在基于miRNA的癌症早期检测领域具有显著的技术、产品和市场优势，是该领域的全球领导者之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1329980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2558652879","title":"MIRXES-B08月11日主力净流入4.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2558652879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558652879?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 16:15","pubTimestamp":1754900109,"startTime":"0","endTime":"0","summary":"08月11日, MIRXES-B股价涨0.91%，报收33.16元，成交金额1482.9万元，换手率0.16%，振幅6.21%，量比1.68。MIRXES-B今日主力资金净流入4.7万元，上一交易日主力净流出0万元。该股近5个交易日上涨6.16%，主力资金累计净流出26.8万元；近20日主力资金累计净流出842.4万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811164834a4819e29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811164834a4819e29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2557408327","title":"MIRXES-B08月06日主力净流入44.5万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2557408327","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557408327?lang=zh_cn&edition=fundamental","pubTime":"2025-08-06 16:15","pubTimestamp":1754468150,"startTime":"0","endTime":"0","summary":"08月06日, MIRXES-B股价涨4.26%，报收32.80元，成交金额719.5万元，换手率0.08%，振幅4.45%，量比0.74。MIRXES-B今日主力资金净流入44.5万元，上一交易日主力净流出0万元。该股近5个交易日上涨6.67%，主力资金累计净流出57.1万元；近20日主力资金累计净流出1187.3万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806170752a6d63a6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806170752a6d63a6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2555227000","title":"MIRXES-B07月31日主力净流出61万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2555227000","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555227000?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 16:15","pubTimestamp":1753949718,"startTime":"0","endTime":"0","summary":"07月31日, MIRXES-B股价跌0.65%，报收30.55元，成交金额570.6万元，换手率0.07%，振幅1.95%，量比0.54。MIRXES-B今日主力资金（超大单+大单）净流出61万元，上一交易日主力净流出0万元。|07月31日主力加仓幅度排名||#|股票简称|主力净额占比|#|宏基集团控股|2.81%|#|高地股份|2.07%|#|嘉鼎国际集团|2.02%|#|...|...|#2204|MIRXES-B|-0.01%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170027a46d31bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170027a46d31bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2554175330","title":"觅瑞、NAGAWA联合发起万人癌筛，鸠山由纪夫应邀助力亚洲癌症预防","url":"https://stock-news.laohu8.com/highlight/detail?id=2554175330","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554175330?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 12:04","pubTimestamp":1753416253,"startTime":"0","endTime":"0","summary":"7月23日，在日本第93代内阁总理大臣鸠山由纪夫的见证下，新加坡RNA液体活检领域上市企业Mirxes觅瑞集团与日本生物医药企业 NAGAWA 药品株式会社联合发起万人筛查项目，并签署战略合作备忘录。该项合作也整合了觅瑞创新的miRNA 检测技术、NAGAWA 本地化制造和市场推广优势，标志着亚洲癌症早筛领域进入技术 + 产业 + 慈善协同发展的新阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725120726a4627ca8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725120726a4627ca8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2553620244","title":"MIRXES-B07月24日主力净流出115.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2553620244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553620244?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 16:16","pubTimestamp":1753344962,"startTime":"0","endTime":"0","summary":"07月24日, MIRXES-B股价跌0.97%，报收30.55元，成交金额1788.1万元，换手率0.21%，振幅5.67%，量比1.18。MIRXES-B今日主力资金净流出115.4万元，上一交易日主力净流出0万元。该股近5个交易日下跌7.42%，主力资金累计净流出77.4万元；近20日主力资金累计净流出1871.2万元，其中净流出天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724170432a460f04b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724170432a460f04b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2553473223","title":"《大行》国证国际：22只非A+H股份可望成为港股通新贵 当中15只在今年新上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2553473223","media":"AASTOCKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553473223?lang=zh_cn&edition=fundamental","pubTime":"2025-07-21 11:31","pubTimestamp":1753068682,"startTime":"0","endTime":"0","summary":"国证国际发表研究报告指，恒指公司将于8月22日发布上半年检讨结果，相关变动将于9月8日生效。由于恒生综合指数的变动将影响港股通名单，其变动受到投资者的高度重视。该行基于平均市值及换手率两个指标计算，得出22只非A+H股份可望成为港股通新贵，当中15只在今年新上市。该行未有计入东亚银行，虽然该股的市值达标，但可能因换手率不足而未能重获港股通资格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721175701a6b7b5d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721175701a6b7b5d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01729","02473","03677","06613","06681","02648","06168","09606","02276","02007","CTRYY","CHFHY","02629","BK4177","02050","02643","02610","03288","01333","09678","02609","02589","06603","603288","00506","603345","01783","YANG","BK4614"],"gpt_icon":0},{"id":"2551005113","title":"觅瑞MIRXES：“借道”“零人”第三方 “擦边”布局限制类业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2551005113","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551005113?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 09:18","pubTimestamp":1752628680,"startTime":"0","endTime":"0","summary":"基于上述情形，觅瑞或“左手倒右手”，“借道”宝晟“擦边”实现上述业务布局。紧随上述股权转让完成后，嘉年分别由杭州觅瑞健康及杭州觅因持有70%及30%。觅瑞披露称，由于相关业务及运营根据中国法律受外商投资限制，嘉年于2023年11月6日订立加入杭州合约安排的加入协议。可见，上市前，觅瑞通过置出子公司的方式，不再从事外商限制类或禁止类业务。对于受让方宝晟，觅瑞称其系独立第三方。嘉年属于双方合资的企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071609191995442ae0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071609191995442ae0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2551188785","title":"MIRXES-B07月14日遭主力抛售133.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551188785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551188785?lang=zh_cn&edition=fundamental","pubTime":"2025-07-14 16:15","pubTimestamp":1752480919,"startTime":"0","endTime":"0","summary":"07月14日，MIRXES-B股价收平报30.85元，成交金额762.0万元，换手率0.09%，振幅2.43%，量比0.57。MIRXES-B今日主力资金净流出133.2万元，上一交易日主力净流出130.5万元。该股近5个交易日下跌0.48%，主力资金累计净流出597.8万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出4593.1万元，其中净流出天数为19日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714165604a44975a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714165604a44975a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2550617370","title":"MIRXES-B07月10日遭主力抛售152.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550617370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550617370?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 16:15","pubTimestamp":1752135351,"startTime":"0","endTime":"0","summary":"07月10日, MIRXES-B股价跌1.12%，报收31.00元，成交金额902.5万元，换手率0.10%，振幅4.78%，量比0.61。MIRXES-B今日主力资金净流出152.6万元，上一交易日主力净流出113.0万元。该股近5个交易日下跌3.09%，主力资金累计净流出701.7万元，其中3个交易日为股价上涨时净流出；近20日主力资金累计净流出4330.5万元，其中净流出天数为18日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170034a6a13ba8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170034a6a13ba8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2550656935","title":"觅瑞MIRXES：自诩“唯一获批”现信披疑云 核心产品特异性或低于国内两款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2550656935","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550656935?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 22:25","pubTimestamp":1752071114,"startTime":"0","endTime":"0","summary":"而在上述两款产品或均属于用于胃癌筛查的分子诊断IVD产品的情况下，觅瑞自称系全球范围内唯一一家获得分子胃癌筛查IVD产品监管批准的公司，信息披露现疑云。在此情况下，觅瑞的核心产品的特异性，或低于国内两款胃癌基因甲基化检测产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709223045a44091ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709223045a44091ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2549458598","title":"MIRXES-B(02629)股价下跌8.219%，现价港币$30.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2549458598","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549458598?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 15:35","pubTimestamp":1751873700,"startTime":"0","endTime":"0","summary":"[下跌股]MIRXES-B(02629) 股价在下午03:35比前收市价下跌8.219%，现股价为港币$30.15。至目前为止，今日最高价为$32.85，而最低价为$30.15。总成交量为50.42万股，总成交金额为港币$1.583千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2507072205/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2548841699","title":"医疗IPO沸腾了","url":"https://stock-news.laohu8.com/highlight/detail?id=2548841699","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548841699?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 08:35","pubTimestamp":1751502900,"startTime":"0","endTime":"0","summary":"医疗IPO市场热潮再起，迎来高光时刻。在2025年上半年港股完成的IPO中，医疗健康企业以9家的数目独占鳌头，成为当之无愧的IPO数量之最行业。同时，A股科创板也重新为医疗企业敞开了IPO大门。如今，历经两年的蛰伏与磨砺，医疗健康IPO终于迎来了破晓的曙光。从细分行业来看，创新药无疑撑起了本轮港股医疗健康IPO的繁荣。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703083915a72b749b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703083915a72b749b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","LU1064131003.USD","BK0028","BK0196","LU1655091616.SGD","LU1997245094.SGD","BK0060","BK0012","LU0405327494.USD","BK0239","09606","LU2148510915.USD","LU2328871848.SGD","LU1997244956.HKD","LU1969619763.USD","159891","LU1997245177.USD","LU1064130708.USD","02315","600276","LU1328615791.USD","BK0183","01276","02629","LU2488822045.USD","LU2495084118.USD","LU0405327148.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":87,"code":"91000000","status":"200"}]}}